
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is poised to have strong market potential with its leading drug, Jakafi, in the rare blood cancer and graft versus host disease space, as well as a diverse portfolio of marketed drugs in rheumatoid arthritis, leukemia, and different types of cancer. The recent approval of Opzelura for atopic dermatitis and upcoming approval for vitiligo further solidifies Incyte's presence in the dermatology market. With positive early response data for its drug, Incyte looks to compete closely with Revolution Medicines' zoldonrasib and aims to preserve chemo delivery. Based on its current assets and promising pipeline, Incyte's valuation using a 9% discount rate and 2% terminal growth rate results in an EV of approximately $28B and a 12-month price target of $140 per share. Risks to consider include potential delays in securing approvals for late-stage candidates and failure to generate favorable data from ongoing programs.
Bears say
Incyte is showing declining revenues and a limited pipeline with only a few drugs in development. Additionally, the current success of their leading drug, Jakafi, is heavily reliant on partnerships with other companies like Novartis and Lilly. Their latest product launch, Opzelura, may provide some short-term revenue, but it is not enough to sustain long-term growth. Furthermore, recent CMS win and EU label momentum may improve their prospects, but it is not enough to offset the overall negative outlook for the company.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares